Summary by Moomoo AI
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ISSUED A NOTICE ON APRIL 2, 2024 ANNOUNCING THE PROGRESS OF ITS SHARE REPURCHASE PROGRAM. The plan was first disclosed on March 27, 2024 and will be implemented from March 26 to September 25, 2024. The repurchase amount is expected to be RMB100 billion to RMB20 billion and the repurchase price will not exceed RMB30 per share. The purpose of the repurchase is for employee shareholding schemes or equity incentives. To date, the Company has not repurchased any shares. Resusstar Pharmaceuticals undertakes to select a time to repurchase based on market conditions and to fulfill its obligation to disclose information in a timely manner, reminding investors to be aware of investment risks.